Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial

OBJECTIVE: To evaluate the efficacy and safety of infliximab through 1 year in patients with psoriatic arthritis (PsA) enrolled in the IMPACT 2 trial. METHODS: In this double blind, placebo controlled, phase III study, 200 patients with active PsA were randomised to receive infusions of infliximab 5...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kavanaugh, A, Krueger, G G, Beutler, A, Guzzo, C, Zhou, B, Dooley, L T, Mease, P J, Gladman, D D, de Vlam, K, Geusens, P P, Birbara, C, Halter, D G, Antoni, C
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2007
Assuntos:
Extended Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1856065/
https://ncbi.nlm.nih.gov/pubmed/17114188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2006.058339
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados